A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT ID: NCT01464034
Last Updated: 2022-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
136 participants
INTERVENTIONAL
2011-11-30
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01665794
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04176718
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
NCT00603447
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT03256045
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01246063
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Carfilzomib, Pomalidomide, Dexamethasone
All eligible subjects will receive the study intervention of Carfilzomib, Pomalidomide, and Dexamethasone.
Carfilzomib
IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
Pomalidomide
PO daily on Days 1-21, every 28 Days
Dexamethasone
40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carfilzomib
IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
Pomalidomide
PO daily on Days 1-21, every 28 Days
Dexamethasone
40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Relapsed or refractory to the most recently received therapy.
* All pts must have received prior lenalidomide therapy and been determined to be refractory, relapsed, or intolerant.
* Measurable disease, as indicated by one or more of the following:
Serum M-protein ≥ 0.5 g/dL Urine Bence Jones protein ≥ 200 mg/24 hr Elevated Free Light Chain as per IMWG criteria, and abnormal ratio
* Pts must be ≥ 18 years of age
* Life expectancy of more than 3 months
* ECOG PS of 0-2
* Adequate hepatic function, with bilirubin \< 2 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 times ULN
* Uric acid must be within laboratory normal range
* CrCl ≥ 50 mL/min
* Additional Laboratory Requirements ANC ≥1.0 x 109/L Hgb ≥8 g/dL(transfusion permitted) Platelet count ≥50.0 x 109/L
* Screening ANC should be independent of granulocyte-and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for at least 2 weeks
* Pts may receive RBC or platelet transfusions, if clinically indicated, in accordance with institutional guidelines
* Screening platelet count should be independent of platelet transfusions for at least 2 weeks.
* Written informed consent in accordance with federal, local, and institutional guidelines
* FCBP must agree to ongoing pregnancy testing
* FCBP must have a negative serum or urine pregnancy test and agree to birth control.
* Male pts must agree to never have unprotected sexual contact with a female who can become pregnant and must agree to either completely abstain from sexual contact with females who are pregnant or are able to become pregnant. The patient must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks for any reason that his sexual partner may be pregnant.
* Male pts cannot donate semen or sperm while taking pomalidomide and for 28 days after completing the study.
* All pts must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
* Pts must agree to take enteric-coated aspirin 81 mg orally daily, or if history of prior thrombotic disease, must be fully anticoagulated with warfarin (INR 2-3) or be treated with full-dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism (PE)at the investigator's discretion
Exclusion Criteria
* Use of any other experimental drug or therapy within 21 days prior to first dose
* Exposure to any prior chemotherapy, steroid use, or other myeloma treatment within 14 days prior to first dose. Pts currently on long term steroids do not require any washout period. in addition, steroid use for spinal cord compression is permitted and does not require a washout period.
* Radiation therapy within 14 days prior to first dose
* Known allergies to carfilzomib or Captisol
* POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
* Current diagnosis of plasma cell leukemia
* Waldenström's macroglobulinemia
* Major surgery within 21 days prior to first dose
* Pregnant or lactating females
* Congestive heart failure (NYHA class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention or myocardial infarction in the previous six months prior to first dose.
* Uncontrolled hypertension
* Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose
* Pts receiving active treatment or intervention for any other malignancy or pts who, at the Investigator's discretion, may require active treatment or intervention for any other malignancy within 8 months of starting study treatment.
* Serious psychiatric or medical conditions that could interfere with treatment
* Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment
* Contraindication to any of the required concomitant drugs, including proton-pump inhibitor (e.g. lansoprazole), enteric-coated aspirin or if a history of prior thrombotic disease, warfarin or low molecular weight heparin
* Pts in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g. due to pre-existing pulmonary, cardiac, or renal impairment
* Pts with primary systemic amyloidosis
* Pts who have received prior treatment with carfilzomib (Phase II only)
* Pts who have received prior treatment with pomalidomide (Phase II only)
* Pts who have received prior treatment with both carfilzomib \& pomalidomide (Phase I only)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Celgene Corporation
INDUSTRY
Criterium, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jatin Shah, MD
Role: PRINCIPAL_INVESTIGATOR
AMyC
Brian GM Durie, MD
Role: PRINCIPAL_INVESTIGATOR
AMyC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
The John Theurer Cancer Center @ Hackensack UMC
Hackensack, New Jersey, United States
Columbia University
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center
Houston, Texas, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284-90. doi: 10.1182/blood-2015-05-643320. Epub 2015 Sep 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IST-CAR-521
Identifier Type: OTHER
Identifier Source: secondary_id
PO-MM-PI-0034
Identifier Type: OTHER
Identifier Source: secondary_id
AMyC 10-MM-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.